Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D Trial (SELECT‐D: 12m)
Andrea Marshall, Mark N. Levine, Catherine St. Hill, Danielle Hale, Jenny Thirlwall, Veronica Wilkie, Karen French, Ajay Kakkar, Anand Lokare, Anthony Maraveyas, Oliver Chapman, Azra Arif, Stavros Petrou, Mandy Maredza, Richard Hobbs, Janet Dunn, Annie Young
Topics & Concepts
MedicineRivaroxabanPulmonary embolismHazard ratioPlaceboRandomizationDeep veinRandomized controlled trialConfidence intervalInternal medicineSurgeryThrombosisWarfarinAtrial fibrillationAlternative medicinePathologyVenous Thromboembolism Diagnosis and ManagementHeparin-Induced Thrombocytopenia and ThrombosisChemotherapy-induced cardiotoxicity and mitigation